% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Janiri:902381,
author = {Janiri, Delfina and Moser, Dominik A. and Doucet, Gaelle E.
and Luber, Maxwell J. and Rasgon, Alexander and Lee, Won Hee
and Murrough, James W. and Sani, Gabriele and Eickhoff,
Simon B. and Frangou, Sophia},
title = {{S}hared {N}eural {P}henotypes for {M}ood and {A}nxiety
{D}isorders {A} {M}eta-{A}nalysis of 226 {T}ask-{R}elated
{F}unctional {I}maging {S}tudies},
journal = {Focus},
volume = {19},
number = {2},
issn = {1541-4108},
address = {Arlington, Va.},
publisher = {American Psychiatric Publ.},
reportid = {FZJ-2021-04215},
pages = {256 - 263},
year = {2021},
note = {Kein Post-print vorhanden},
abstract = {Importance: Major depressive disorder, bipolar disorder,
posttraumatic stress disorder, and anxiety disorders are
highly comorbid and have shared clinical features. It is not
yet known whether their clinical overlap is reflected at the
neurobiological level.Objective: To detect transdiagnostic
convergence in abnormalities in task-related brain
activation.Data source: Task-related functional magnetic
resonance imaging articles published in PubMed, Web of
Science, and Google Scholar during the last decade comparing
control individuals with patients with mood, posttraumatic
stress, and anxiety disorders were examined.Study selection:
Following Preferred Reporting Items for Systematic Reviews
and Meta-analyses reporting guidelines, articles were
selected if they reported stereotactic coordinates of
whole-brain-based activation differences between adult
patients and control individuals.Data extraction and
synthesis: Coordinates of case-control differences coded by
diagnosis and by cognitive domain based on the research
domain criteria were analyzed using activation likelihood
estimation.Main outcomes and measures: Identification of
transdiagnostic clusters of aberrant activation and
quantification of the contribution of diagnosis and
cognitive domain to each cluster.Results: A total of 367
experiments (major depressive disorder, 149; bipolar
disorder, 103; posttraumatic stress disorder, 55; and
anxiety disorders, 60) were included comprising observations
from 4507 patients and 4755 control individuals. Three
right-sided clusters of hypoactivation were identified
centered in the inferior prefrontal cortex/insula (volume,
2120 mm3), the inferior parietal lobule (volume, 1224 mm3),
and the putamen (volume, 888 mm3); diagnostic differences
were noted only in the putamen (χ23 = 8.66; P = .03), where
hypoactivation was more likely in bipolar disorder
(percentage contribution = $72.17\%).$ Tasks associated with
cognitive systems made the largest contribution to each
cluster (percentage contributions $>29\%).$ Clusters of
hyperactivation could only be detected using a less
stringent threshold. These were centered in the
perigenual/dorsal anterior cingulate cortex (volume, 2208
mm3), the left amygdala/parahippocampal gyrus (volume, 2008
mm3), and the left thalamus (volume, 1904 mm3). No
diagnostic differences were observed (χ23 < 3.06; P > .38),
while tasks associated with negative valence systems made
the largest contribution to each cluster (percentage
contributions $>49\%).$ All findings were robust to the
moderator effects of age, sex, and magnetic field strength
of the scanner and medication.Conclusions and relevance: In
mood disorders, posttraumatic stress disorder, and anxiety
disorders, the most consistent transdiagnostic abnormalities
in task-related brain activity converge in regions that are
primarily associated with inhibitory control and salience
processing. Targeting these shared neural phenotypes could
potentially mitigate the risk of affective morbidity in the
general population and improve outcomes in clinical
populations.Conflict of interest statementConflict of
Interest Disclosures: In the past 5 years, Dr Murrough has
provided consultation services to Boehreinger Ingelheim,
Sage Therapeutics, FSV7, Novartis, Allergan, Fortress
Biotech, Janssen Research and Development,
Medavante-Prophase, and Global Medical Education and has
received research support from Avanir Pharmaceuticals Inc.
Dr Murrough is named on a patent pending for neuropeptide Y
as a treatment for mood and anxiety disorders. No other
disclosures were reported.},
cin = {INM-7},
ddc = {610},
cid = {I:(DE-Juel1)INM-7-20090406},
pnm = {5252 - Brain Dysfunction and Plasticity (POF4-525)},
pid = {G:(DE-HGF)POF4-5252},
typ = {PUB:(DE-HGF)16},
doi = {10.1176/appi.focus.19206},
url = {https://juser.fz-juelich.de/record/902381},
}